The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG).


Journal

European child & adolescent psychiatry
ISSN: 1435-165X
Titre abrégé: Eur Child Adolesc Psychiatry
Pays: Germany
ID NLM: 9212296

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 21 05 2021
accepted: 01 09 2021
medline: 10 7 2023
pubmed: 23 10 2021
entrez: 22 10 2021
Statut: ppublish

Résumé

ADHD is the most common neurodevelopmental disorder presenting to child and adolescent mental health, paediatric, and primary care services. Timely and effective interventions to address core ADHD symptoms and co-occurring problems are a high priority for healthcare and society more widely. While much research has reported on the benefits and adverse effects of different interventions for ADHD, these individual research reports and the reviews, meta-analyses and guidelines summarizing their findings are sometimes inconsistent and difficult to interpret. We have summarized the current evidence and identified several methodological issues and gaps in the current evidence that we believe are important for clinicians to consider when evaluating the evidence and making treatment decisions. These include understanding potential impact of bias such as inadequate blinding and selection bias on study outcomes; the relative lack of high-quality data comparing different treatments and assessing long-term effectiveness, adverse effects and safety for both pharmacological and non-pharmacological treatments; and the problems associated with observational studies, including those based on large national registries and comparing treatments with each other. We highlight key similarities across current international clinical guidelines and discuss the reasons for divergence where these occur. We discuss the integration of these different perspective into a framework for person/family-centered evidence-based practice approach to care that aims to achieve optimal outcomes that prioritize individual strengths and impairments, as well as the personal treatment targets of children and their families. Finally, we consider how access to care for this common and impairing disorder can be improved in different healthcare systems.

Identifiants

pubmed: 34677682
doi: 10.1007/s00787-021-01871-x
pii: 10.1007/s00787-021-01871-x
pmc: PMC8532460
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1337-1361

Informations de copyright

© 2021. Crown.

Références

American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, fifth edition, DSM-5. American Psychiatric Publishing, Washington, DC
doi: 10.1176/appi.books.9780890425596
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164(6):942–948
pubmed: 17541055 doi: 10.1176/ajp.2007.164.6.942
Fayyad J, Sampson NA, Hwang I, Adamowski T, Aguilar-Gaxiola S, Al-Hamzawi A et al (2017) The descriptive epidemiology of DSM-IV Adult ADHD in the World Health Organization World Mental Health Surveys. Atten Defic Hyperact Disord 9(1):47–65
pubmed: 27866355 doi: 10.1007/s12402-016-0208-3
Hinshaw SP, Scheffler RM (2018) ADHD in the twenty-first century: Biology, context, policy, and the need for integrative perspective. In: Banaschewski T, Coghill D, Zuddas A (eds) Oxford textbook of ADHD. Oxford University Press, Oxford, pp 9–18
Mulraney M, Coghill D (2018) Quality of life and impairment in ADHD. In: Banaschewski T, Coghill D, Zuddas A (eds) Oxford textbook of attention deficit hyperactivity disorder. Oxford University Press, Oxford, pp 161–169
Coghill D, Hodgkins P (2016) Health-related quality of life of children with attention-deficit/hyperactivity disorder versus children with diabetes and healthy controls. Eur Child Adolesc Psychiatry 25(3):261–271
pubmed: 26054300 doi: 10.1007/s00787-015-0728-y
Able SL, Johnston JA, Adler LA, Swindle RW (2007) Functional and psychosocial impairment in adults with undiagnosed ADHD. Psychol Med 37(1):97–107
pubmed: 16938146 doi: 10.1017/S0033291706008713
Ertan C, Ozcan OO, Pepele MS (2012) Paediatric trauma patients and attention deficit hyperactivity disorder: correlation and significance. Emerg Med J 29(11):911–914
pubmed: 22215173 doi: 10.1136/emermed-2011-200298
Ruiz-Goikoetxea M, Cortese S, Magallon S, Aznarez-Sanado M, Alvarez Zallo N, Luis EO et al (2018) Risk of poisoning in children and adolescents with ADHD: a systematic review and meta-analysis. Sci Rep 8(1):7584
pubmed: 29765117 pmcid: 5953942 doi: 10.1038/s41598-018-25893-9
Ostergaard SD, Dalsgaard S, Faraone SV, Munk-Olsen T, Laursen TM (2017) Teenage Parenthood and Birth Rates for Individuals With and Without Attention-Deficit/Hyperactivity Disorder: A Nationwide Cohort Study. J Am Acad Child Adolesc Psychiatry 56(7):578–84 e3
pubmed: 28647009 doi: 10.1016/j.jaac.2017.05.003
Barkley RA, Fischer M, Edelbrock C, Smallish L (1991) The adolescent outcome of hyperactive children diagnosed by research criteria—III. Mother-child interactions, family conflicts and maternal psychopathology. J Child Psychol Psychiatry 32(2):233–255
pubmed: 2033106 doi: 10.1111/j.1469-7610.1991.tb00304.x
Young S, Moss D, Sedgwick O, Fridman M, Hodgkins P (2015) A meta-analysis of the prevalence of attention deficit hyperactivity disorder in incarcerated populations. Psychol Med 45(2):247–258
pubmed: 25066071 doi: 10.1017/S0033291714000762
Bolte S, Poustka L, Geurts H (2018) Austism spectrum disorder. In: Banaschewski T, Coghill D, Zuddas A (eds) Oxford teaxtbook of ADHD. Oxford University Press, Oxford, pp 227–234
Hollis C, Pennant M, Cuenca J, Glazebrook C, Kendall T, Whittington C et al (2016) Clinical effectiveness and patient perspectives of different treatment strategies for tics in children and adolescents with Tourette syndrome: a systematic review and qualitative analysis. Health Technol Assess 20(4):1–450
pubmed: 26786936 pmcid: 4781241 doi: 10.3310/hta20040
Simonoff E (2018) Intelectual impairment and neurogenetic disorders. In: Banaschewski T, Coghill D, Zuddas A (eds) Oxford teaxtbook of ADHD. Oxford University Press, Oxford, pp 235–246
Thapar A, van Goozen S (2018) Conduct disorder in ADHD. In: Banaschewski T, Coghill D, Zuddas A (eds) Oxford teaxtbook of ADHD. Oxford University Press, Oxford, pp 193–200
Oxley C, Stringaris A (2018) Comorbidity: depression and anxiety. In: Banaschewski T, Coghill D, Zuddas A (eds) Oxford textbook of ADHD. Oxford University Press, Oxfiord, pp 206–214
Lecendreux M, Cortese S (2007) Sleep problems associated with ADHD: a review of current therapeutic options and recommendations for the future. Expert Rev Neurother 7(12):1799–1806
pubmed: 18052772 doi: 10.1586/14737175.7.12.1799
Wilens T, Carrellas N, Biederman J (2018) ADHD and substance misuse. In: Banaschewski T, Coghill D, Zuddas A (eds) Oxford teaxtbook of ADHD. Oxford University Press, Oxford, pp 215–226
Philipsen A (2006) Differential diagnosis and comorbidity of attention-deficit/hyperactivity disorder (ADHD) and borderline personality disorder (BPD) in adults. Eur Arch Psychiatry Clin Neurosci 256(Suppl 1):i42–i46
pubmed: 16977551 doi: 10.1007/s00406-006-1006-2
Williams AE, Giust JM, Kronenberger WG, Dunn DW (2016) Epilepsy and attention-deficit hyperactivity disorder: links, risks, and challenges. Neuropsychiatr Dis Treat 12:287–296
pubmed: 26929624 pmcid: 4755462
Cortese S, Moreira Maia CR, Rohde LA, Morcillo-Penalver C, Faraone SV (2014) Prevalence of obesity in attention-deficit/hyperactivity disorder: study protocol for a systematic review and meta-analysis. BMJ Open 4(3):e004541
pubmed: 24643169 pmcid: 3963068 doi: 10.1136/bmjopen-2013-004541
Cortese S, Sun S, Zhang J, Sharma E, Chang Z, Kuja-Halkola R et al (2018) Association between attention deficit hyperactivity disorder and asthma: a systematic review and meta-analysis and a Swedish population-based study. Lancet Psychiatry 5(9):717–726
pubmed: 30054261 doi: 10.1016/S2215-0366(18)30224-4
Economics DA (2019) the Social and Economic costs of ADHD in Australia. Australian ADHD Professionals Association, Melbourne
Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S et al (2018) Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 5(9):727–738
pubmed: 30097390 pmcid: 6109107 doi: 10.1016/S2215-0366(18)30269-4
Sonuga-Barke EJ, Brandeis D, Cortese S, Daley D, Ferrin M, Holtmann M et al (2013) Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. Am J Psychiatry 170(3):275–289
pubmed: 23360949 doi: 10.1176/appi.ajp.2012.12070991
Swanson JM, Arnold LE, Jensen P, Hinshaw SP, Hechtman LT, Conners CK et al (2018) Long- term outcomes in the Multimodal Treatment study of Children with ADHD (the MTA): from beginning to end. In: Banaschewski T, Coghill D, Zuddas A (eds) The Oxford textbook of ADHD. Oxford University Press, Oxford, pp 315–332
Coghill D (2019) Debate: are stimulant medications for attention-deficit/hyperactivity disorder effective in the long term? (For). J Am Acad Child Adolesc Psychiatry 58(10):938–939
pubmed: 31515164 doi: 10.1016/j.jaac.2019.07.002
Posner J, Kass E, Hulvershorn L (2014) Using stimulants to treat ADHD-related emotional lability. Curr Psychiatry Rep 16(10):478
pubmed: 25135778 pmcid: 4243526 doi: 10.1007/s11920-014-0478-4
Lichtenstein P, Halldner L, Zetterqvist J, Sjolander A, Serlachius E, Fazel S et al (2012) Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 367(21):2006–2014
pubmed: 23171097 pmcid: 3664186 doi: 10.1056/NEJMoa1203241
Chang Z, Quinn PD, Hur K, Gibbons RD, Sjolander A, Larsson H et al (2017) Association between medication use for attention-deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiat 74(6):597–603
doi: 10.1001/jamapsychiatry.2017.0659
Chang Z, Ghirardi L, Quinn PD, Asherson P, D’Onofrio BM, Larsson H (2019) Risks and benefits of attention-deficit/hyperactivity disorder medication on behavioral and neuropsychiatric outcomes: a qualitative review of pharmacoepidemiology studies using linked prescription databases. Biol Psychiatry 86(5):335–343
pubmed: 31155139 pmcid: 6697582 doi: 10.1016/j.biopsych.2019.04.009
Caye A, Swanson J, Thapar A, Sibley M, Arseneault L, Hechtman L et al (2016) Life span studies of ADHD-conceptual challenges and predictors of persistence and outcome. Curr Psychiatry Rep 18(12):111
pubmed: 27783340 pmcid: 5919196 doi: 10.1007/s11920-016-0750-x
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928
pubmed: 22008217 pmcid: 3196245 doi: 10.1136/bmj.d5928
Guyatt GH, Oxman A, Vist GE, Kunz R, Falck-Ytter Y, Schunemann HJ (2008) GRADE: what is “quality of evidence” and why is it important to clinicians? BMJ 336:995–998
pubmed: 18456631 pmcid: 2364804 doi: 10.1136/bmj.39490.551019.BE
Storebo OJ, Krogh HB, Ramstad E, Moreira-Maia CR, Holmskov M, Skoog M et al (2015) Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ 351:h5203
pubmed: 26608309 pmcid: 4659414 doi: 10.1136/bmj.h5203
Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S et al (2018) Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials 19(1):407
pubmed: 30060754 pmcid: 6066921 doi: 10.1186/s13063-018-2733-1
National Institute for Health and Clinical Excellence (2018) Attention deficit hyperactivity disorder: diagnosis and management: update. Department of Health
NICE (2019) Hypertension in adults: diagnosis and management (NG 136). National Institute for Health and Care Excellence, London
NICE (2017) Asthma: diagnosis, monitoring and chronic asthma management (NG 80). National Institute for Health and Care Excellence
NICE (2018) Attention deficit hyperactivity disorder: diagnosis and management. National Institute for Health and Clinical Excellence, London
Cortese S, Ferrin M, Brandeis D, Buitelaar J, Daley D, Dittmann RW et al (2015) Cognitive training for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials. J Am Acad Child Adolesc Psychiatry 54(3):164–174
pubmed: 25721181 pmcid: 4382075 doi: 10.1016/j.jaac.2014.12.010
Cortese S, Ferrin M, Brandeis D, Holtmann M, Aggensteiner P, Daley D et al (2016) Neurofeedback for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials. J Am Acad Child Adolesc Psychiatry 55(6):444–455
pubmed: 27238063 doi: 10.1016/j.jaac.2016.03.007
Daley D, van der Oord S, Ferrin M, Danckaerts M, Doepfner M, Cortese S et al (2014) Behavioral interventions in attention-deficit/hyperactivity disorder: a meta-analysis of randomized controlled trials across multiple outcome domains. J Am Acad Child Adolesc Psychiatry 53(8):835–847
pubmed: 25062591 doi: 10.1016/j.jaac.2014.05.013
Stevenson J, Buitelaar J, Cortese S, Ferrin M, Konofal E, Lecendreux M et al (2014) Research review: the role of diet in the treatment of attention-deficit/hyperactivity disorder—an appraisal of the evidence on efficacy and recommendations on the design of future studies. J Child Psychol Psychiatry 55(5):416–427
pubmed: 24552603 doi: 10.1111/jcpp.12215
Cortese S (2019) Debate: are stimulant medications for attention-deficit/hyperactivity disorder effective in the long term? J Am Acad Child Adolesc Psychiatry 58(10):936
pubmed: 31254608 doi: 10.1016/j.jaac.2019.04.029
Swanson JM (2019) Debate: are stimulant medications for attention-deficit/hyperactivity disorder effective in the long term? (against). J Am Acad Child Adolesc Psychiatry 58(10):936–938
pubmed: 31515165 doi: 10.1016/j.jaac.2019.07.001
Buitelaar JK, Michelson D, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A et al (2007) A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry 61(5):694–699
pubmed: 16893523 doi: 10.1016/j.biopsych.2006.03.066
Coghill DR, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson CS et al (2014) Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design. J Am Acad Child Adolesc Psychiatry 53(6):647–657
pubmed: 24839883 doi: 10.1016/j.jaac.2014.01.017
Newcorn JH, Harpin V, Huss M, Lyne A, Sikirica V, Johnson M et al (2016) Extended-release guanfacine hydrochloride in 6–17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study. J Child Psychol Psychiatry 57(6):717–728
pubmed: 26871297 doi: 10.1111/jcpp.12492
Matthijssen AM, Dietrich A, Bierens M, Kleine Deters R, van de Loo-Neus GHH, van den Hoofdakker BJ et al (2019) Continued benefits of methylphenidate in ADHD after 2 years in clinical practice: a randomized placebo-controlled discontinuation study. Am J Psychiatry 176(9):754–762
pubmed: 31109200 doi: 10.1176/appi.ajp.2019.18111296
Banaschewski T, Buitelaar J, Coghill DR, Sergeant JA, Sonuga-Barke E, Zuddas A et al (2009) The MTA at 8. J Am Acad Child Adolesc Psychiatry 48(11):1120–1121 (author reply 3-4)
pubmed: 19855221 doi: 10.1097/CHI.0b013e3181bac557
Gerlach M, Banaschewski T, Coghill D, Rohde LA, Romanos M (2017) What are the benefits of methylphenidate as a treatment for children and adolescents with attention-deficit/hyperactivity disorder? Attent Deficit Hyperact Dis 9(1):1–3
doi: 10.1007/s12402-017-0220-2
Coghill DR, Banaschewski T, Nagy P, Otero IH, Soutullo C, Yan B et al (2017) Long-term safety and efficacy of lisdexamfetamine dimesylate in children and adolescents with ADHD: A Phase IV, 2-year. Open Label Study Eur CNS Drugs 31(7):625–638
doi: 10.1007/s40263-017-0443-y
Klatte R, Strauss B, Fluckiger C, Rosendahl J (2018) Adverse effects of psychotherapy: protocol for a systematic review and meta-analysis. Syst Rev 7(1):135
pubmed: 30193585 pmcid: 6128985 doi: 10.1186/s13643-018-0802-x
Allan A, Chacko A (2018) Adverse events in behavioral parent training for children with ADHD: an under-appreciated phenomenon. ADHD Rep 26:4–9
doi: 10.1521/adhd.2018.26.1.4
Sonuga-Barke EJ (2016) Can medication effects be determined using national registry data? A cautionary reflection on risk of bias in “big data” analytics. Biol Psychiatry 80(12):893–895
pubmed: 27839559 doi: 10.1016/j.biopsych.2016.10.002
Lichtenstein P, Larsson H (2013) Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 368(8):776
pubmed: 23425178
Mohr-Jensen C, Muller Bisgaard C, Boldsen SK, Steinhausen HC (2019) Attention-deficit/hyperactivity disorder in childhood and adolescence and the risk of crime in young adulthood in a Danish nationwide study. J Am Acad Child Adolesc Psychiatry 58(4):443–452
pubmed: 30768385 doi: 10.1016/j.jaac.2018.11.016
Chang Z, Lichtenstein P, Langstrom N, Larsson H, Fazel S (2016) Association between prescription of major psychotropic medications and violent reoffending after prison release. JAMA 316(17):1798–1807
pubmed: 27802545 pmcid: 5100822 doi: 10.1001/jama.2016.15380
Chang Z, D’Onofrio BM, Quinn PD, Lichtenstein P, Larsson H (2016) Medication for attention-deficit/hyperactivity disorder and risk for depression: a nationwide longitudinal cohort study. Biol Psychiat 80(12):916–922
pubmed: 27086545 doi: 10.1016/j.biopsych.2016.02.018
Man KKC, Coghill D, Chan EW, Lau WCY, Hollis C, Liddle E et al (2017) Association of risk of suicide attempts with methylphenidate treatment. JAMA Psychiat 74(10):1048–1055
doi: 10.1001/jamapsychiatry.2017.2183
Chen Q, Sjolander A, Runeson B, D’Onofrio BM, Lichtenstein P, Larsson H (2014) Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ 348:g3769
pubmed: 24942388 pmcid: 4062356 doi: 10.1136/bmj.g3769
Quinn PD, Chang Z, Hur K, Gibbons RD, Lahey BB, Rickert ME et al (2017) ADHD medication and substance-related problems. Am J Psychiatry 174(9):877–885
pubmed: 28659039 pmcid: 5581231 doi: 10.1176/appi.ajp.2017.16060686
Steinhausen HC, Bisgaard C (2014) Substance use disorders in association with attention-deficit/hyperactivity disorder, co-morbid mental disorders, and medication in a nationwide sample. Eur Neuropsychopharmacol 24(2):232–241
pubmed: 24314850 doi: 10.1016/j.euroneuro.2013.11.003
Man KK, Coghill D, Chan EW, Lau WC, Hollis C, Liddle E et al (2016) Methylphenidate and the risk of psychotic disorders and hallucinations in children and adolescents in a large health system. Transl Psychiatry 6(11):e956
pubmed: 27845780 pmcid: 5314128 doi: 10.1038/tp.2016.216
Ghirardi L, Chen Q, Chang Z, Kuja-Halkola R, Skoglund C, Quinn PD et al (2020) Use of medication for attention-deficit/hyperactivity disorder and risk of unintentional injuries in children and adolescents with co-occurring neurodevelopmental disorders. J Child Psychol Psychiatry 61(2):140–147
pubmed: 31625605 doi: 10.1111/jcpp.13136
Ghirardi L, Larsson H, Chang Z, Chen Q, Quinn PD, Hur K et al (2019) Attention-Deficit/Hyperactivity Disorder Medication and Unintentional Injuries in Children and Adolescents. J Am Acad Child Adolesc Psychiatry. https://doi.org/10.1016/j.jaac.2019.06.010
doi: 10.1016/j.jaac.2019.06.010 pubmed: 31302218 pmcid: 6954332
Raman SR, Marshall SW, Haynes K, Gaynes BN, Naftel AJ, Sturmer T (2013) Stimulant treatment and injury among children with attention deficit hyperactivity disorder: an application of the self-controlled case series study design. Inj Prev 19(3):164–170
pubmed: 23143347 doi: 10.1136/injuryprev-2012-040483
Mikolajczyk R, Horn J, Schmedt N, Langner I, Lindemann C, Garbe E (2015) Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study. JAMA Pediatr 169(4):391–395
pubmed: 25686215 doi: 10.1001/jamapediatrics.2014.3275
Man KK, Chan EW, Coghill D, Douglas I, Ip P, Leung LP et al (2015) Methylphenidate and the risk of trauma. Pediatrics 135(1):40–48
pubmed: 25511122 doi: 10.1542/peds.2014-1738
Dalsgaard S, Leckman JF, Mortensen PB, Nielsen HS, Simonsen M (2015) Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Lancet Psychiatry 2(8):702–709
pubmed: 26249301 doi: 10.1016/S2215-0366(15)00271-0
Chang Z, Lichtenstein P, D’Onofrio BM, Sjolander A, Larsson H (2014) Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiat 71(3):319–325
doi: 10.1001/jamapsychiatry.2013.4174
Jangmo A, Stalhandske A, Chang Z, Chen Q, Almqvist C, Feldman I et al (2019) Attention-deficit/hyperactivity disorder, school performance, and effect of medication. J Am Acad Child Adolesc Psychiatry 58(4):423–432
pubmed: 30768391 pmcid: 6541488 doi: 10.1016/j.jaac.2018.11.014
Lu Y, Sjolander A, Cederlof M, D’Onofrio BM, Almqvist C, Larsson H et al (2017) Association between medication use and performance on higher education entrance tests in individuals with attention-deficit/hyperactivity disorder. JAMA Psychiat 74(8):815–822
doi: 10.1001/jamapsychiatry.2017.1472
Kanters S, Ford N, Druyts E, Thorlund K, Mills EJ, Bansback N (2016) Use of network meta-analysis in clinical guidelines. Bull World Health Organ 94(10):782–784
pubmed: 27843171 pmcid: 5043215 doi: 10.2471/BLT.16.174326
Del Giovane C, Cortese S, Cipriani A (2019) Combining pharmacological and nonpharmacological interventions in network meta-analysis in psychiatry. JAMA Psychiat 76:867–868
doi: 10.1001/jamapsychiatry.2019.0574
Wong ICK, Banaschewski T, Buitelaar J, Cortese S, Dopfner M, Simonoff E et al (2019) Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorder-outcome measures beyond symptom control and clinical trials. Lancet Psychiatry 6(6):528–537
pubmed: 31122482 doi: 10.1016/S2215-0366(19)30096-3
Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M et al (2013) Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry 54(3):227–246
pubmed: 23294014 doi: 10.1111/jcpp.12036
Arns M, Strehl U (2013) Evidence for efficacy of neurofeedback in ADHD? Am J Psychiatry 170(7):799–800
pubmed: 23820843 doi: 10.1176/appi.ajp.2013.13020208
Sonuga-Barke E, Brandeis D, Cortese S, Daley D, Danckaerts M, Dopfner M et al (2013) Response to Chronis-Tuscano et al. and Arns and Strehl. Am J Psychiatry 170(7):800–802
pubmed: 23820834 doi: 10.1176/appi.ajp.2013.13020208r
Micoulaud-Franchi JA, Salvo F, Bioulac S, Fovet T (2016) Neurofeedback in attention-deficit/hyperactivity disorder: efficacy. J Am Acad Child Adolesc Psychiatry 55(12):1091–1092
pubmed: 27871645 doi: 10.1016/j.jaac.2016.09.493
Simkin DR, Arnold LE, Lubar J (2016) Neurofeedback in attention-deficit/hyperactivity disorder: evaluation difficulties. J Am Acad Child Adolesc Psychiatry 55(12):1090–1091
pubmed: 27871644 doi: 10.1016/j.jaac.2016.09.494
Cortese S, Brandeis D, Holtmann M, Sonuga-Barke EJ, European AGG (2016) The European ADHD guidelines group replies. J Am Acad Child Adolesc Psychiatry 55(12):1092–1093
pubmed: 27871646 doi: 10.1016/j.jaac.2016.09.492
Bussalb A, Congedo M, Barthelemy Q, Ojeda D, Acquaviva E, Delorme R et al (2019) Clinical and experimental factors influencing the efficacy of neurofeedback in ADHD: a meta-analysis. Front Psychiatry Front Res Found 10:35
doi: 10.3389/fpsyt.2019.00035
Strehl U, Aggensteiner P, Wachtlin D, Brandeis D, Albrecht B, Arana M et al (2017) Neurofeedback of slow cortical potentials in children with attention-deficit/hyperactivity disorder: a multicenter randomized trial controlling for unspecific effects. Front Hum Neurosci 11:135
pubmed: 28408873 pmcid: 5374218 doi: 10.3389/fnhum.2017.00135
Excellence (2018) NIfHaC. Attention defificit hyperactivity disorder: diagnosis and management
(DGKJP) DGfK-uJPuP, (DGPPN) DGfPuPPuN, (DGPSJ) DGfSuJ (2018) Langfassung der interdisziplinären evidenz- und konsensbasierten (S3) Leitlinie „Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend- und Erwachsenenalter”
Zorgstandaard ADHD (2019) Amsterdam: GGZ Standaarden. www.ggzstandaarden.nl/zorgstandaarden/adhd
TDAH (2017) GdtdlGdPCslITeeTpDdAcH. Guía de Práctica Clínica sobre las Intervenciones Terapéuticas en el Trastorno por Déficit de Atención con Hiperactividad (TDAH). Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad., (IACS) IAdCdlS
Wolraich ML, Hagan JF Jr, Allan C, Chan E, Davison D, Earls M et al (2019) Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. https://doi.org/10.1542/peds.2019-2528
doi: 10.1542/peds.2019-2528 pubmed: 31570649
Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G et al (2010) AGREE II: advancing guideline development, reporting, and evaluation in health care. Prev Med 51(5):421–424
pubmed: 20728466 doi: 10.1016/j.ypmed.2010.08.005
Bachmann CJ, Roessner V, Glaeske G, Hoffmann F (2014) Trends in psychopharmacologic treatment of tic disorders in children and adolescents in Germany. Eur Child Adolesc Psychiatry 24:199–207
pubmed: 24888751 doi: 10.1007/s00787-014-0563-6
Libutzki B, Ludwig S, May M, Jacobsen RH, Reif A, Hartman CA (2019) Direct medical costs of ADHD and its comorbid conditions on basis of a claims data analysis. Eur Psychiatry 58:38–44
pubmed: 30802682 doi: 10.1016/j.eurpsy.2019.01.019
Akmatov MK, Steffen A, Holstiege J, Hering R, Schulz M, Batzing J (2018) Trends and regional variations in the administrative prevalence of attention-deficit/hyperactivity disorder among children and adolescents in Germany. Sci Rep 8(1):17029
pubmed: 30451896 pmcid: 6242899 doi: 10.1038/s41598-018-35048-5
Holden SE, Jenkins-Jones S, Poole CD, Morgan CL, Coghill D, Currie CJ (2013) The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010). Child Adolesc Psychiatry Ment Health 7(1):34
pubmed: 24119376 pmcid: 3856565 doi: 10.1186/1753-2000-7-34
Alliance CAR (2018) Canadian ADHD Practice Guidelines. Fourth Edition. Canadian ADHD Resource Alliance
Group M (1999) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA cooperative group. Multimodal treatment study of children with ADHD. Arch Gen Psychiatry 56(12):1073–1086
doi: 10.1001/archpsyc.56.12.1073
Coghill D, Seth S (2015) Effective management of attention-deficit/hyperactivity disorder (ADHD) through structured re-assessment: the Dundee ADHD clinical care pathway. Child Adolesc Psychiatry Ment Health 9:52
pubmed: 26587055 pmcid: 4652349 doi: 10.1186/s13034-015-0083-2
Fernandez de la Cruz L, Simonoff E, Halperin JM, Eugene Arnold L, Stringaris A (2015) Treatment of children with attention deficit hyperactivity disorder (ADHD) and irritability: Results from the multimodal treatment study of children with ADHD (MTA). J Am Acad Child Adolesc Psychiatry 54(1):62–70
pubmed: 25524791 pmcid: 4284308 doi: 10.1016/j.jaac.2014.10.006
Jensen PS (1999) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56(12):1073–1086
doi: 10.1001/archpsyc.56.12.1073
Boland H, DiSalvo M, Fried R, Woodworth KY, Wilens T, Faraone SV et al (2020) A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. J Psychiatr Res 123:21–30
pubmed: 32014701 doi: 10.1016/j.jpsychires.2020.01.006
Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S et al (2018) Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry. https://doi.org/10.1016/S2215-0366(18)30269-4
doi: 10.1016/S2215-0366(18)30269-4 pubmed: 30477652 pmcid: 6109107
Aggensteiner PM, Brandeis D, Millenet S, Hohmann S, Ruckes C, Beuth S et al (2019) Slow cortical potentials neurofeedback in children with ADHD: comorbidity, self-regulation and clinical outcomes 6 months after treatment in a multicenter randomized controlled trial. Eur Child Adolesc Psychiatry 28(8):1087–1095
pubmed: 30610380 doi: 10.1007/s00787-018-01271-8
Coghill DR, Hayward D, Rhodes SM, Grimmer C, Matthews K (2014) A longitudinal examination of neuropsychological and clinical functioning in boys with attention deficit hyperactivity disorder (ADHD): improvements in executive functioning do not explain clinical improvement. Psychol Med 44(5):1087–1099
pubmed: 23866120 doi: 10.1017/S0033291713001761
Ferrin M, Taylor E (2011) Child and caregiver issues in treatment of attention deficit-hyperactivity disorder: education, adherence and treatment choice. Future Neurol 6:399–413
doi: 10.2217/fnl.11.5
Schatz NK, Fabiano GA, Cunningham CE, dosReis S, Waschbusch DA, Jerome S et al (2015) Systematic review of patients’ and parents’ preferences for ADHD treatment options and processes of care. Patient 8(6):483–497
pubmed: 25644223 doi: 10.1007/s40271-015-0112-5
Tully LA, Hawes DJ, Doyle FL, Sawyer MG, Dadds MR (2019) A national child mental health literacy initiative is needed to reduce childhood mental health disorders. Aust N Z J Psychiatry 53(4):286–290
pubmed: 30654614 doi: 10.1177/0004867418821440
Hospital TRCs (2017) RCH National Child Health Poll. Poll 8. Child mental health problems: Can parents spot the signs?
NICE (2018) Attention defificit hyperactivity disorder: diagnosis and management: NICE guideline 87. London
Eke H, Ford T, Newlove-Delgado T, Price A, Young S, Ani C et al (2019) Transition between child and adult services for young people with attention-deficit hyperactivity disorder (ADHD): findings from a British national surveillance study. Br J Psychiatry 217:1–7
Trochetto de Oliveira C, Dias A (2018) Psychoeducation for attention deficit/hyperactivity disorder: what, how and who shall we inform? Trends Psychol 26(1):263–281
Ferrin M, Perez-Ayala V, El-Abd S, Lax-Pericall T, Jacobs B, Bilbow A et al (2016) A randomized controlled trial evaluating the efficacy of a psychoeducation program for families of children and adolescents with ADHD in the UK: results after a 6-month follow-up. J Atten Disord 24(5):768–779
pubmed: 26838557 doi: 10.1177/1087054715626509
Fortney JC, Unutzer J, Wrenn G, Pyne JM, Smith GR, Schoenbaum M et al (2017) A tipping point for measurement-based care. Psychiatr Serv 68(2):179–188
pubmed: 27582237 doi: 10.1176/appi.ps.201500439
Adamo N, Seth S, Coghill D (2015) Pharmacological treatment of attention-deficit/hyperactivity disorder: assessing outcomes. Expert Rev Clin Pharmacol 8(4):383–397
pubmed: 26109097 doi: 10.1586/17512433.2015.1050379
Caye A, Swanson JM, Coghill D, Rohde LA (2018) Treatment strategies for ADHD: an evidence-based guide to select optimal treatment. Mol Psychiatry 24(3):390–408
pubmed: 29955166 doi: 10.1038/s41380-018-0116-3
Pelham WE Jr, Fabiano GA, Waxmonsky JG, Greiner AR, Gnagy EM, Pelham WE 3rd et al (2016) Treatment sequencing for childhood ADHD: a multiple-randomization study of adaptive medication and behavioral interventions. J Clin Child Adolesc Psychol 45(4):396–415
pubmed: 26882332 pmcid: 4930381 doi: 10.1080/15374416.2015.1105138
Nobel E, Hoekstra PJ, Agnes Brunnekreef J, Messink-de Vries DEH, Fischer B, Emmelkamp PMG et al (2019) Home-based parent training for school-aged children with attention-deficit/hyperactivity disorder and behavior problems with remaining impairing disruptive behaviors after routine treatment: a randomized controlled trial. Eur Child Adolesc Psychiatry 29(3):395–440
pubmed: 31332524 pmcid: 7056677 doi: 10.1007/s00787-019-01375-9
Dopfner M, Hautmann C, Dose C, Banaschewski T, Becker K, Brandeis D et al (2017) ESCAschool study: trial protocol of an adaptive treatment approach for school-age children with ADHD including two randomised trials. BMC Psychiatry 17(1):269
pubmed: 28738794 pmcid: 5525245 doi: 10.1186/s12888-017-1433-9
Zinnow T, Banaschewski T, Fallgatter AJ, Jenkner C, Philipp-Wiegmann F, Philipsen A et al (2018) ESCAlate—adaptive treatment approach for adolescents and adults with ADHD: study protocol for a randomized controlled trial. Trials 19(1):280
pubmed: 29776383 pmcid: 5960079 doi: 10.1186/s13063-018-2665-9
Geissler J, Jans T, Banaschewski T, Becker K, Renner T, Brandeis D et al (2018) Individualised short-term therapy for adolescents impaired by attention-deficit/hyperactivity disorder despite previous routine care treatment (ESCAadol)-Study protocol of a randomised controlled trial within the consortium ESCAlife. Trials 19(1):254
pubmed: 29703226 pmcid: 5921777 doi: 10.1186/s13063-018-2635-2
Becker K, Banaschewski T, Brandeis D, Dose C, Hautmann C, Holtmann M et al (2020) Individualised stepwise adaptive treatment for 3-6-year-old preschool children impaired by attention-deficit/hyperactivity disorder (ESCApreschool): study protocol of an adaptive intervention study including two randomised controlled trials within the consortium ESCAlife. Trials 21(1):56
pubmed: 31918739 pmcid: 6953462 doi: 10.1186/s13063-019-3872-8
Barbaresi WJ, Campbell L, Diekroger EA, Froehlich TE, Liu YH, O’Malley E et al (2020) Society for developmental and behavioral pediatrics clinical practice guideline for the assessment and treatment of children and adolescents with complex attention-deficit/hyperactivity disorder. J Dev Behav Pediatr 41(Suppl 2S):S35–S57
pubmed: 31996577 doi: 10.1097/DBP.0000000000000770
Coghill D, Danckaerts M (2018) Organizing and delivering treatment for ADHD. In: Banaschewski T, Coghill D, Zuddas A (eds) Oxford textbook for ADHD. Oxford University Press, Oxford, pp 417–425
Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugue M, Carpentier PJ et al (2010) European consensus statement on diagnosis and treatment of adult ADHD: the European network Adult ADHD. BMC Psychiatry 10:67
pubmed: 20815868 pmcid: 2942810 doi: 10.1186/1471-244X-10-67
Katzman MA, Bilkey TS, Chokka PR, Fallu A, Klassen LJ (2017) Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. BMC Psychiatry 17(1):302
pubmed: 28830387 pmcid: 5567978 doi: 10.1186/s12888-017-1463-3
Hinshaw SP (2007) Moderators and mediators of treatment outcome for youth with ADHD: understanding for whom and how interventions work. J Pediatr Psychol 32(6):664–675
pubmed: 17264086 doi: 10.1093/jpepsy/jsl055
van Emmerik-van OK, Vedel E, Kramer FJ, Blankers M, Dekker JJM, van den Brink W et al (2019) Integrated cognitive behavioral therapy for ADHD in adult substance use disorder patients: results of a randomized clinical trial. Drug Alcohol Depend 197:28–36
doi: 10.1016/j.drugalcdep.2018.12.023
Coles EK, Pelham Iii WE, Fabiano GA, Gnagy EM, Burrows-MacLean L, Wymbs BT et al (2019) Randomized trial of first-line behavioral intervention to reduce need for medication in children with ADHD. J Clin Child Adolesc Psychol 49:1–15
Van der Oord S, Prins PJ, Oosterlaan J, Emmelkamp PM (2008) Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: a meta-analysis. Clin Psychol Rev 28(5):783–800
pubmed: 18068284 doi: 10.1016/j.cpr.2007.10.007
Catala-Lopez F, Hutton B, Nunez-Beltran A, Mayhew AD, Page MJ, Ridao M et al (2015) The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: protocol for a systematic review and network meta-analysis of randomized controlled trials. Syst Rev 4:19
pubmed: 25875125 pmcid: 4357151 doi: 10.1186/s13643-015-0005-7
Bernard S, Turk J (2009) Developing mental health services for children and adolescents with learning disabilities: a toolkit for clinicians. Royal College of Psychiatrists, London
Evans SW, Owens JS, Mautone JA, DuPaul GJ, Power TJ (2014) Toward a comprehensive, life course model of care for youth with ADHD. In: Weist M, Lever C, Bradshaw C, Owens J (eds) Handbook of school mental health, 2nd edn. Springer, New York, pp 413–426
doi: 10.1007/978-1-4614-7624-5_30
Evans SW, Serpell ZN, Schultz B, Pastor D (2007) Cumulative benefits of secondary school-based treatment of students with ADHD. School Psych Rev 36:256–273
doi: 10.1080/02796015.2007.12087943
Richardson M, Moore DA, Gwernan-Jones R, Thompson-Coon J, Ukoumunne O, Rogers M et al (2015) Non-pharmacological interventions for attention-deficit/hyperactivity disorder (ADHD) delivered in school settings: systematic reviews of quantitative and qualitative research. Health Technol Assess 19(45):1–470
pubmed: 26691209 pmcid: 4781165 doi: 10.3310/hta19450
Kazdin AE (2019) Annual research review: expanding mental health services through novel models of intervention delivery. J Child Psychol Psychiatry 60(4):455–472
pubmed: 29900543 doi: 10.1111/jcpp.12937
Sayal K, Prasad V, Daley D, Ford T, Coghill D (2018) ADHD in children and young people: prevalence, care pathways, and service provision. Lancet Psychiatry 5(2):175–186
pubmed: 29033005 doi: 10.1016/S2215-0366(17)30167-0
Wright N, Moldavsky M, Schneider J, Chakrabarti I, Coates J, Daley D et al (2015) Practitioner review: pathways to care for ADHD—a systematic review of barriers and facilitators. J Child Psychol Psychiatry 56(6):598–617
pubmed: 25706049 pmcid: 5008177 doi: 10.1111/jcpp.12398
Kim WJ, American Academy of C, Adolescent Psychiatry Task Force on Workforce N (2003) Child and adolescent psychiatry workforce: a critical shortage and national challenge. Acad Psychiatry 27(4):277–282
pubmed: 14754851 doi: 10.1176/appi.ap.27.4.277
RCPSYCH (2019) Children and youngpeople with mental healthproblems and access to NHS treatments. Royal college of Psychiatrists, London
Kazdin AE (2017) Addressing the treatment gap: a key challenge for extending evidence-based psychosocial interventions. Behav Res Ther 88:7–18
pubmed: 28110678 doi: 10.1016/j.brat.2016.06.004
Chacko A, Scavenius C (2018) Bending the curve: a community-based behavioral parent training model to address ADHD-related concerns in the voluntary sector in Denmark. J Abnorm Child Psychol 46(3):505–517
pubmed: 28536873 doi: 10.1007/s10802-017-0310-9
Myers K, Vander Stoep A, Zhou C, McCarty CA, Katon W (2015) Effectiveness of a telehealth service delivery model for treating attention-deficit/hyperactivity disorder: a community-based randomized controlled trial. J Am Acad Child Adolesc Psychiatry 54(4):263–274
pubmed: 25791143 pmcid: 4406418 doi: 10.1016/j.jaac.2015.01.009
Pfiffner L, DuPaul G (2015) Treatment of ADHD in School Settings. In: Barkley R (ed) Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. The Guilford Press, New York, NY, pp 596–629
Sayal K, Merrell C, Tymms P, Kasim A (2015) Academic Outcomes Following a School-Based RCT for ADHD: 6-Year Follow-Up. J Atten Disord 24(1):66–72
pubmed: 25555626 doi: 10.1177/1087054714562588
Hollis C, Falconer CJ, Martin JL, Whittington C, Stockton S, Glazebrook C et al (2017) Annual research review: digital health interventions for children and young people with mental health problems—a systematic and meta-review. J Child Psychol Psychiatry 58(4):474–503
pubmed: 27943285 doi: 10.1111/jcpp.12663

Auteurs

David Coghill (D)

Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
Murdoch Children's Research Institute, Melbourne, Australia.
Royal Children's Hospital, Melbourne, Australia.

Tobias Banaschewski (T)

Child and Adolescent Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.

Samuele Cortese (S)

Centre for Innovation in Mental Health, School of Psychology, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK.
Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK.
Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK.
Solent NHS Trust, Southampton, UK.
Hassenfeld Children's Hospital at NYU Langone, New York University Child Study Center, New York City, New York, USA.
Division of Psychiatry and Applied Psychology, School of Medicine, University of Nottingham, Nottingham, UK.
NIHR MindTech Mental Health MedTech Cooperative & Centre for ADHD and Neurodevelopmental Disorders Across the Lifespan CANDAL, Institute of Mental Health, University of Nottingham, Nottingham, UK.

Philip Asherson (P)

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Daniel Brandeis (D)

Child and Adolescent Psychiatry and Psychotherapy, Medical Faculty Mannheim, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.
Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.
Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland.
Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.

Jan Buitelaar (J)

Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands.

David Daley (D)

Division of Psychiatry and Applied Psychology, School of Medicine, University of Nottingham, Nottingham, UK.
NIHR MindTech Mental Health MedTech Cooperative & Centre for ADHD and Neurodevelopmental Disorders Across the Lifespan CANDAL, Institute of Mental Health, University of Nottingham, Nottingham, UK.

Marina Danckaerts (M)

Research Group of Developmental Psychiatry, Center for Developmental Psychiatry, KU Leuven, Kapucijnenvoer 7, Blok H, 3000, Leuven, Belgium.
Department of Child and Adolescent Psychiatry, UPC KU Leuven, Leuven, Belgium.

Ralf W Dittmann (RW)

Paediatric Psychopharmacology, Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany.

Manfred Doepfner (M)

Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Faculty of Medicine, University Hospital Cologne, University of Cologne, Cologne, Germany.

Maite Ferrin (M)

Haringey CAMHS, NHS, and ReCognition Health, London, UK.

Chris Hollis (C)

Division of Psychiatry and Applied Psychology, School of Medicine, University of Nottingham, Nottingham, UK.
NIHR MindTech Mental Health MedTech Cooperative & Centre for ADHD and Neurodevelopmental Disorders Across the Lifespan CANDAL, Institute of Mental Health, University of Nottingham, Nottingham, UK.

Martin Holtmann (M)

LWL-University Hospital for Child and Adolescent Psychiatry, Ruhr-University Bochum, Hamm, Germany.

Santosh Paramala (S)

Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK.

Edmund Sonuga-Barke (E)

Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK.

César Soutullo (C)

Louis A Fallace Department of Psychiatry and Behavioral Science, University of Texas, Houston, TX, USA.

Hans-Christoph Steinhausen (HC)

Department of Child and Adolescent Psychiatry, Aarhus University, Aarhus, Denmark.
Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry, Zurich, Switzerland.
Clinical Psychology and Epidemiology, Institute of Psychology, University of Basel, Basel, Switzerland.
Department of Child and Adolescent Mental Health, University of Southern Denmark, Odense, Denmark.
Child and Adolescent Mental Health Centre, Capital Region Psychiatry, Copenhagen, Denmark.

Saskia Van der Oord (S)

Clinical Psychology, KU Leuven, Leuven, Belgium.
Developmental Psychology, University of Amsterdam, Amsterdam, The Netherlands.

Ian C K Wong (ICK)

School of Pharmacy, University College London, London, UK.

Alessandro Zuddas (A)

Child and Adolescent Neuropsychiatry Unit, Department of Biomedical Sciences, University of Cagliari and Antonio Cao Paediatric Hospital, G. Brotzu Hospital Trust, Cagliari, Italy.

Emily Simonoff (E)

LWL-University Hospital for Child and Adolescent Psychiatry, Ruhr-University Bochum, Hamm, Germany. emily.simonoff@kcl.ac.uk.
Department of Child and Adolescent Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. emily.simonoff@kcl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH